Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 652 News
1 - 10of about 652 News
December 03, 2021
Not intended for U.S. and UK Media
Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
READ MORE
November 15, 2021
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease
READ MORE
November 11, 2021
Not intended for U.S. and UK Media
New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction
READ MORE
November 10, 2021
Not intended for U.S. and UK Media
Bayer Submits Aflibercept for regulatory approval in the EU and Japan for Retinopathy of Prematurity in premature babies
READ MORE
November 09, 2021
Third quarter of 2021:
Bayer grows sales and earnings significantly
READ MORE
November 09, 2021
Effective January 1, 2022:
Rodrigo Santos named member of the Board of Management, Bayer AG, and President of the Crop Science division
READ MORE
November 08, 2021
Not intended for U.S. and UK Media - The American Society of Nephrology (ASN)’s Kidney Week 2021:
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
READ MORE
November 05, 2021
Not intended for U.S. and UK Media - The American Heart Association Scientific Sessions 2021:
Bayer to present data from cardiovascular portfolio, including analyses from the comprehensive finerenone clinical trial program, VOYAGER PAD (Xarelto™) and the VICTORIA trial (Verquvo™)
READ MORE
October 29, 2021
Not intended for U.S. and UK Media
European Patent Office maintained Bayer patent on the once-daily administration of rivaroxaban (Xarelto™)
READ MORE
October 27, 2021
Not intended for U.S. and UK Media – The American Society of Nephrology (ASN)’s Kidney Week 2021:
Bayer to present new data from comprehensive finerenone clinical trial program
READ MORE
1 - 10of about 652 News
1 - 10of about 652 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more